CCM
VRTX icon

CAAS Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

CAAS Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$291K Buy
+600
New +$280K 0.03% 329
2020
Q2 		– Sell
-900
Closed -$214K – 485
2020
Q1 		$214K Buy
+900
New +$206K 0.02% 205

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAAS Capital Management's VRTX Position: Q1 2025 in Review

CAAS Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2025: 100 shares worth $48.5K. The stake represents 0.01% of the portfolio and ranks #426 among its holdings. This is a return to the name: CAAS Capital Management previously reported a position in VRTX as recently as Q1 2021.

CAAS Capital Management first reported a position in VRTX in Q1 2021 and has held it in 2 quarters since. The position peaked at $4.18M in Q1 2021. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • CAAS Capital Management held 100 shares of Vertex Pharmaceuticals worth $48.5K as of Q1 2025.
  • Vertex Pharmaceuticals was a new CAAS Capital Management position in Q1 2025.
  • Vertex Pharmaceuticals made up 0.01% of CAAS Capital Management's portfolio in Q1 2025, its #426 holding.
  • CAAS Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • CAAS Capital Management's Vertex Pharmaceuticals position peaked at $4.18M in Q1 2021.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.